Bendamustine mitoxantrone and rituximab (BMR): a new effective regimen for refractory or relapsed indolent lymphomas.

Weide, Rudolf; Heymanns, Jochen; Gores, Annette; Köppler, Hubert

Weide, Rudolf; Heymanns, Jochen; Gores, Annette; Köppler, Hubert.

Affiliation

Weide R; Haematology/Oncology Group Practice, Koblenz, Germany. haem.onc.ko@t-online.de

Leuk Lymphoma ; 43(2): 327-31, 2002 Feb.

Article in En | MEDLINE | ID: mdl-11999564

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Lymphoma, B-Cell/drug therapy; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols/toxicity; Bendamustine Hydrochloride; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy; Middle Aged; Mitoxantrone/administration & dosage; Nitrogen Mustard Compounds/administration & dosage; Remission Induction; Rituximab; Salvage Therapy

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, B-Cell Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2002 Type: Article Affiliation country: Germany

Search on Google

XML

PubMed Links